A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients

Journal of Psychopharmacology

Volumn 26, Issue 6, 2012, Pages 813-818

  Wei, Zhiyun ^a,b   Wang, Lei ^a,b   Zhang, Mengmeng ^a,b   Xuan, Jiekun ^a,b   Wang, Yang ^a,b   Liu, Baocheng ^a,b   Shao, Liyan ^a,b   Li, Jun ^a   Zeng, Zhen ^a,b   Li, Tao ^a,b   Liu, Jie ^a,b   Wang, Ti ^a,b   Zhang, Ming ^a,b   Qin, Shengying ^a,b   Xu, Yifeng ^c   Feng, Guoyin ^c   He, Lin ^a,b,d   Xing, Qinghe ^a,d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c SHANGHAI MENTAL HEALTH CENTER   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Chinese; histamine; HRH3; pharmacogenetics; risperidone; schizophrenia

Indexed keywords

HISTAMINE H3 RECEPTOR; PALIPERIDONE; RISPERIDONE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DNA MARKER; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOME ANALYSIS; GENOTYPE; HISTAMINE H3 RECEPTOR GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MONOTHERAPY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RECEPTOR GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; GENOTYPE; HUMANS; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, HISTAMINE H3; RISPERIDONE; SCHIZOPHRENIA;

EID: 84862135579     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111405358     Document Type: Article

References (35)

1. Cardno AG, Gottesman II. Twin studies of schizophrenia: From bow-and-arrow concordances to Star Wars Mx and functional genomics. Am J Med Genet. 2000 ; 97: 12-17
2. Chazot PL, Shenton FC. H3 histamine receptors: The gene knockout data so far. Curr Anaesth Crit Care. 2004 ; 15: 23-28
3. Consortium TIH. The International HapMap Project. Nature. 2003 ; 426: 789-796
4. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002 ; 346: 16-22
5. Esbenshade TA, Browman KE, Bitner RS, et al. The histamine H3 receptor: An attractive target for the treatment of cognitive disorders. Br J Pharmacol. 2008 ; 154: 1166-1181
6. Ferrada C, Ferre S, Casado V, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology. 2008 ; 55: 190-197
7. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002 ; 106: 323-330
8. Gao B, Gu JZ, She CW, et al. Mutations in IHH, encoding Indian hedgehog, cause brachydactyly type A-1. Nat Genet. 2001 ; 28: 386-388
9. Gu B, Wang L, Zhang A-P, et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics. 2008 ; 18: 721-727
10. Heck AH, Haffmans PM, de Groot IW, et al. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res. 2000 ; 46: 97-105
11. Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol. 2001 ; 59: 415-419
12. Ito C. The role of the central histaminergic system on schizophrenia. Drug News Perspect. 2004 ; 17: 383-387
13. Kane JM. Schizophrenia. N Engl J Med. 1996 ; 334: 34-41
14. Kimchi-Sarfaty C, Oh JM, Kim I-W, et al. A 'Silent' Polymorphism in the MDR1 Gene Changes Substrate Specificity. Science. 2007 ; 315: 525-528
15. Lane H-Y, Chang Y-C, Chiu C-C, et al. Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. Am J Psychiatry. 2002 ; 159: 1593-1595
16. Lane H-Y, Lin C-C, Huang C-H, et al. Risperidone response and 5-HT6 receptor gene variance: Genetic association analysis with adjustment for nongenetic confounders. Schizophr Res. 2004 ; 67: 63-70
17. Lencz T, Robinson DG, Xu K, et al. DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients. Am J Psychiatry. 2006 ; 163: 529-531
18. Leysen JE, Janssen PM, Gommeren W, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992 ; 41: 494-508
19. Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl) propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther. 2007 ; 320: 365-375
20. Liu BC, Zhang J, Wang L, et al. HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients. Pharmacogenomics. 2010 ; 11: 685-692
21. Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol. 1999 ; 55: 1101-1107
22. Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005 ; 10: 79-104
23. Morisset S, Rouleau A, Ligneau X, et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature. 2000 ; 408: 860-864
24. Nakai T, Kitamura N, Hashimoto T, et al. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry. 1991 ; 30: 349-356
25. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl. 1997 ; 698: 209-216
26. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962 ; 10: 779-812
27. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995 ; 166: 712-733
28. Prell GD, Green JP, Kaufmann CA, et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: Their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995 ; 14: 93-104
29. Reynolds GP, Yao Z, Zhang X, et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol. 2005 ; 15: 143-151
30. Rodrigues AA, Jansen FP, Leurs R, et al. Interaction of clozapine with the histamine H3 receptor in rat brain. Br J Pharmacol. 1995 ; 114: 1523-1524
31. Rousset F, Raymond M. Testing heterozygote excess and deficiency. Genetics. 1995 ; 140: 1413-1419
32. Shen LX, Basilion JP, Stanton VP. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci USA. 1999 ; 96: 7871-7876
33. Southam E, Cilia J, Gartlon JE, et al. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology. 2008 ; 201: 483-494
34. Supek F, Vlahovicek K. Comparison of codon usage measures and their applicability in prediction of microbial gene expressivity. BMC Bioinformatics. 2005 ; 6: 182
35. Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett. 2007 ; 414: 1-4